EVOLUTION AT MERCK - INVENTING FOR LIFE
BROADEST PROSTATE CANCER PROGRAM WITH
MULTIPLE PH 3 TRIALS ADDRESSING 40% OF PATIENTS
PSA
Primary
Adjuvant
Biochemical
Recurrence (BCR)
Met HSPC
(incl de novo)
mCRPC
Pre-CTx
mCRPC
CTX
mCRPC
Post-CTx
Non-metastatic
CRPC
KN-365 Cohort
C
Ph3 mHSPC Pembro
Enzalutamide
(MO)
KN-199 Cohort
4,5
KN-921 Ph3
Pembro /
Docetaxel
(New trial to be posted) |
KN-199 Cohort
1-3
KEYLYNK-010 Ph3
Pembro/Olaparib
KN-641 Ph3
Non-metastatic
Hormone-sensitive
Asymptomatic
Met
Time
Pembro /
Enzalutamide
PROpel
Ph3 olaparib/
abiraterone
PROfound
Ph3 olaparib
mono
(post-NHA)
ADT
androgen deprivation therapy; BCR = biochemical recurrence; CRPC = castration-resistant prostate cancer; EBRT = external beam radiation therapy; HSPC = hormone-sensitive prostate cancer; PCa = prostate cancer;
RP radical prostatectomy.
*Cl indicates estimated ARCHES approval as of 4Q 2019
Metastatic
Castration-resistant
Symptomatic
= KEYTRUDA combo trials
= Lynparza trials
MERCK
#
Dr. Roy Baynes
|
INVENTING FOR LIFE
55View entire presentation